All Stories

  1. A “Set Point” for Water Homeostasis Disturbed with Altered Kidney Transplantation Outcome

    Article • Journal of the American Society of Nephrology, June 2019, American Society of Nephrology

    M.D. DANIEL G BICHET

  2. GNAS: A New Nephrogenic Cause of Inappropriate Antidiuresis

    Article • Journal of the American Society of Nephrology, April 2019, American Society of Nephrology

    M.D. DANIEL G BICHET

  3. ACUTE AND CHRONIC HYPERGLYCEMIC EFFECTS OF VASOPRESSIN IN NORMAL RATS, INVOLVEMENT OF V 1A RECEPTORS

    Article • AJP Endocrinology and Metabolism, December 2016, American Physiological Society

    M.D. DANIEL G BICHET

  4. Impaired Left Atrial Function in Fabry Disease: A Longitudinal Speckle-Tracking Echocardiography Study

    Article • Journal of the American Society of Echocardiography, December 2016, Elsevier

    M.D. DANIEL G BICHET

  5. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

    Article • Genetics in Medicine, September 2016, Nature

    M.D. DANIEL G BICHET

  6. Functional Recovery of AQP2 Recessive Mutations Through Hetero-Oligomerization with Wild-Type Counterpart

    Article • Scientific Reports, September 2016, Nature

    M.D. DANIEL G BICHET

  7. β3-Adrenoreceptors in the thick ascending limb of Henle and in principal cells of the collecting duct work to concentrate urine

    Article • Kidney International, September 2016, Elsevier

    M.D. DANIEL G BICHET

  8. MAP17 Is a Necessary Activator of Renal Na + /Glucose Cotransporter SGLT2

    Article • Journal of the American Society of Nephrology, June 2016, American Society of Nephrology

    M.D. DANIEL G BICHET

  9. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry

    Article • Journal of Medical Genetics, March 2016, BMJ

    M.D. DANIEL G BICHET

  10. A need for a systematic genetic evaluation of hereditary polyuric patients

    Article • Clinical Kidney Journal, March 2016, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  11. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant)

    Article • Best Practice & Research Clinical Endocrinology & Metabolism, March 2016, Elsevier

    M.D. DANIEL G BICHET

  12. Phenotype of Fabry disease in patients with mutations amenable to migalastat

    Article • Molecular Genetics and Metabolism, February 2016, Elsevier

    M.D. DANIEL G BICHET

  13. The validation of pharmacogenetics in the identification of patients with Fabry disease for treatment with migalastat

    Article • Molecular Genetics and Metabolism, February 2016, Elsevier

    M.D. DANIEL G BICHET

  14. Vasopressin at Central Levels and Consequences of Dehydration

    Article • Annals of Nutrition and Metabolism, January 2016, Karger Publishers

    M.D. DANIEL G BICHET

  15. Approach to the patient with polyuria

    Article • October 2015, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  16. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy

    Article • American Journal of Kidney Diseases, October 2015, Elsevier

    M.D. DANIEL G BICHET

  17. Un diabète insipide peut en cacher un autre ! À propos d’un cas de diabète insipide néphrogénique

    Article • Annales d Endocrinologie, September 2015, Elsevier

    M.D. DANIEL G BICHET

  18. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

    Article • PLoS ONE, August 2015, PLOS

    M.D. DANIEL G BICHET, Mr Myrl D. Holida

  19. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus

    Article • Nature Reviews Nephrology, June 2015, Nature

    M.D. DANIEL G BICHET

  20. Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial

    Article • PLoS ONE, May 2015, PLOS

    M.D. DANIEL G BICHET

  21. Les années 2000

    Article • médecine/sciences, March 2015, EDP Sciences

    M.D. DANIEL G BICHET, Dr Herve Chneiweiss

  22. Improvement in gastrointestinal symptoms observed in the phase 3 FACETS (AT1001-011) study of migalastat in patients affected with Fabry disease

    Article • Molecular Genetics and Metabolism, February 2015, Elsevier

    M.D. DANIEL G BICHET

  23. Long-term efficacy and safety of migalastat compared to enzyme replacement therapy in Fabry disease: Phase 3 study results

    Article • Molecular Genetics and Metabolism, February 2015, Elsevier

    M.D. DANIEL G BICHET

  24. Accurate quantitation of plasma globotriaosylsphingosine (lyso-Gb3) in normal individuals and Fabry disease patients by liquid chromatography–tandem mass spectrometry (LC–MS/MS)

    Article • Molecular Genetics and Metabolism, February 2015, Elsevier

    M.D. DANIEL G BICHET

  25. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats

    Article • Diabetologia, January 2015, Springer Science + Business Media

    M.D. DANIEL G BICHET

  26. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry

    Article • Clinica Chimica Acta, January 2015, Elsevier

    M.D. DANIEL G BICHET, MD, PhD Guillem PINTOS-MORELL

  27. Diabetes Insipidus: Celebrating a Century of Vasopressin Therapy

    Article • Endocrinology, December 2014, Endocrine Society

    M.D. DANIEL G BICHET

  28. Comparison Between Copeptin and Vasopressin in a Population From the Community and in People With Chronic Kidney Disease

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2014, Endocrine Society

    M.D. DANIEL G BICHET

  29. Erratum to: Clinical practice guideline on diagnosis and treatment of hyponatraemia

    Article • Intensive Care Medicine, July 2014, Springer Science + Business Media

    prof djillali annane, M.D. DANIEL G BICHET

  30. Erratum

    Article • Nephrology Dialysis Transplantation, July 2014, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  31. Central vasopressin: dendritic and axonal secretion and renal actions

    Article • Clinical Kidney Journal, May 2014, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  32. A Copeptin-Based Classification of the Osmoregulatory Defects in the Syndrome of Inappropriate Antidiuresis

    Article • Journal of the American Society of Nephrology, April 2014, American Society of Nephrology

    M.D. DANIEL G BICHET

  33. Outcomes of patients treated through the Canadian Fabry disease initiative

    Article • Molecular Genetics and Metabolism, April 2014, Elsevier

    M.D. DANIEL G BICHET

  34. Erratum to: Clinical practice guideline on diagnosis and treatment of hyponatraemia

    Article • Intensive Care Medicine, March 2014, Springer Science + Business Media

    prof djillali annane, M.D. DANIEL G BICHET

  35. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

    Article • AJP Renal Physiology, March 2014, American Physiological Society

    M.D. DANIEL G BICHET

  36. The syndrome of inappropriate antidiuresis: a copeptin-based classification and identification of a novel subtype

    Article • Experimental and Clinical Endocrinology & Diabetes, March 2014, Thieme Publishing Group

    M.D. DANIEL G BICHET

  37. Clinical practice guideline on diagnosis and treatment of hyponatraemia

    Article • Intensive Care Medicine, February 2014, Springer Science + Business Media

    prof djillali annane, M.D. DANIEL G BICHET

  38. Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia

    Article • BANTAO Journal, January 2014, De Gruyter Open Sp. z o.o.

    prof djillali annane, Prof. Goce Spasovski, M.D. DANIEL G BICHET

  39. Section Introduction: Emergent Management of Sodium Disorders

    Article • January 2014, Endocrine Society

    M.D. DANIEL G BICHET

  40. G Protein-Coupled Receptor Mutations and Human Genetic Disease

    Article • January 2014, Springer Science + Business Media

    M.D. DANIEL G BICHET

  41. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families

    Article • Kidney International, January 2014, Elsevier

    M.D. DANIEL G BICHET

  42. Diabètes insipides : nouvelles données génétiques et physiopathologiques

    Article • Annales d Endocrinologie, September 2013, Elsevier

    M.D. DANIEL G BICHET

  43. Diabète insipide néphrogénique héréditaire : quelle prise en charge à l’âge adulte ?

    Article • Néphrologie & Thérapeutique, September 2013, Elsevier

    M.D. DANIEL G BICHET

  44. Transient nephrogenic syndrome of inappropriate antidiuresis: Table 1.

    Article • Clinical Kidney Journal, June 2013, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  45. Urinary concentration: different ways to open and close the tap

    Article • Pediatric Nephrology, June 2013, Springer Science + Business Media

    M.D. DANIEL G BICHET

  46. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects

    Article • Molecular Genetics and Metabolism, May 2013, Elsevier

    M.D. DANIEL G BICHET

  47. A phase 2a study to investigate the effect of a single dose of migalastat HCl, a pharmacological chaperone, on agalsidase activity in subjects with Fabry disease

    Article • Molecular Genetics and Metabolism, February 2013, Elsevier

    Mr Myrl D. Holida, M.D. DANIEL G BICHET

  48. Benefit of enzyme replacement therapy in Fabry disease: Comparison of outcomes in the Canadian Fabry Disease Initiative study

    Article • Molecular Genetics and Metabolism, February 2013, Elsevier

    M.D. DANIEL G BICHET

  49. Clinical effects of neutralizing anti-agalsidase antibodies in patients receiving enzyme replacement therapy in the Canadian Fabry Disease Initiative Study

    Article • Molecular Genetics and Metabolism, February 2013, Elsevier

    M.D. DANIEL G BICHET

  50. A randomized, multicenter, multinational, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms: Baseline demographics and clinical data

    Article • Molecular Genetics and Metabolism, February 2013, Elsevier

    M.D. DANIEL G BICHET

  51. Inherited secondary nephrogenic diabetes insipidus: concentrating on humans

    Article • AJP Renal Physiology, January 2013, American Physiological Society

    M.D. DANIEL G BICHET

  52. Polyuria and Diabetes Insipidus

    Article • January 2013, Elsevier

    M.D. DANIEL G BICHET

  53. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia

    Article • Kidney International, December 2012, Elsevier

    M.D. DANIEL G BICHET

  54. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia

    Article • Kidney International, December 2012, Elsevier

    M.D. DANIEL G BICHET

  55. A defect in vasopressin secretion in autosomal dominant polycystic kidney disease

    Article • Kidney International, November 2012, Elsevier

    M.D. DANIEL G BICHET

  56. Identification and Characterization of an Activating F229V Substitution in the V2 Vasopressin Receptor in an Infant with NSIAD

    Article • Journal of the American Society of Nephrology, September 2012, American Society of Nephrology

    M.D. DANIEL G BICHET

  57. 4. Renal Actions of Vasopressin

    Article • September 2012, Endocrine Society

    M.D. DANIEL G BICHET

  58. Physiopathology of hereditary polyuric states: a molecular view of renal function

    Article • Swiss Medical Weekly, July 2012, EMH Swiss Medical Publishers, Ltd.

    M.D. DANIEL G BICHET

  59. Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD

    Article • Nature Reviews Nephrology, June 2012, Nature

    M.D. DANIEL G BICHET

  60. Vaptans vs medicinal urea

    Article • Clinical Journal of the American Society of Nephrology, April 2012, American Society of Nephrology

    M.D. DANIEL G BICHET

  61. Genetics and diagnosis of central diabetes insipidus

    Article • Annales d Endocrinologie, April 2012, Elsevier

    M.D. DANIEL G BICHET

  62. A Family With Hyponatremia and the Nephrogenic Syndrome of Inappropriate Antidiuresis

    Article • American Journal of Kidney Diseases, April 2012, Elsevier

    M.D. DANIEL G BICHET

  63. P19—Influence of Anti-Agalsidase Antibodies on Clinical Outcomes in the Canadian Fabry Disease Initiative Study

    Article • Clinical Therapeutics, April 2012, Elsevier

    M.D. DANIEL G BICHET

  64. P18—Agalsidase Alfa and Agalsidase Beta have Similar Effects on Outcomes in Fabry Disease: Results From the Canadian Fabry Disease Initiative

    Article • Clinical Therapeutics, April 2012, Elsevier

    M.D. DANIEL G BICHET

  65. Aquaporin-2: new mutations responsible for autosomal-recessive nephrogenic diabetes insipidus--update and epidemiology

    Article • Clinical Kidney Journal, March 2012, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  66. 025 L’hormone antidiurétique (ou vasopressine) est un nouveau facteur de risque du diabète, indépendant. Résultats de la cohorte D.E.S.I.R.

    Article • Diabetes & Metabolism, March 2012, Elsevier

    M.D. DANIEL G BICHET

  67. Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study

    Article • Molecular Genetics and Metabolism, February 2012, Elsevier

    M.D. DANIEL G BICHET

  68. Oral Migalastat HCL (AT1001/GR181314A) as an Investigational Therapy Evaluated in Females with Fabry Disease

    Article • Molecular Genetics and Metabolism, February 2012, Elsevier

    M.D. DANIEL G BICHET

  69. Fabry Disease Mutations Addressable with Migalastat HCl, an Investigational Chaperone Therapy. Screening Results from FACETS, a Phase 3 Study in Male and Female Patients

    Article • Molecular Genetics and Metabolism, February 2012, Elsevier

    M.D. DANIEL G BICHET

  70. Inherited Disorders of the Renal Tubule

    Article • January 2012, Elsevier

    M.D. DANIEL G BICHET

  71. Response of the Renal Inner Medulla to Hypoxia: Possible Defense Mechanisms

    Article • Nephron Physiology, January 2012, Karger Publishers

    M.D. DANIEL G BICHET

  72. Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease

    Article • Blood, July 2011, American Society of Hematology

    M.D. DANIEL G BICHET

  73. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus

    Article • Endocrine, May 2011, Springer Science + Business Media

    M.D. DANIEL G BICHET

  74. Novel mutation in the AVPR2 gene in a Danish male with nephrogenic diabetes insipidus caused by ER retention and subsequent lysosomal degradation of the mutant receptor

    Article • Clinical Kidney Journal, March 2011, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  75. A patient with polyuria and hydronephrosis: answer

    Article • Pediatric Nephrology, February 2011, Springer Science + Business Media

    M.D. DANIEL G BICHET

  76. A patient with polyuria and hydronephrosis: question

    Article • Pediatric Nephrology, February 2011, Springer Science + Business Media

    M.D. DANIEL G BICHET

  77. Agalsidase Alfa and Agalsidase beta Have Similar Effects on Outcomes in Fabry disease– results from the canadian Fabry disease initiative

    Article • Molecular Genetics and Metabolism, February 2011, Elsevier

    M.D. DANIEL G BICHET

  78. The Posterior Pituitary

    Article • January 2011, Elsevier

    M.D. DANIEL G BICHET

  79. Endocrine Control of Water Balance

    Article • January 2011, Wiley

    M.D. DANIEL G BICHET

  80. Contributors

    Article • January 2011, Elsevier

    M.D. DANIEL G BICHET

  81. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?

    Article • Clinica Chimica Acta, December 2010, Elsevier

    M.D. DANIEL G BICHET

  82. Kidney and liver cysts in autosomal dominant polycystic kidney disease

    Article • Nephrology Dialysis Transplantation, September 2010, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  83. A de novo novel missense mutation in AVPR2 with severe nephrogenic diabetes insipidus

    Article • Clinical Kidney Journal, September 2010, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  84. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension?

    Article • AJP Renal Physiology, September 2010, American Physiological Society

    M.D. DANIEL G BICHET

  85. Stimulating Effect of External Myo-Inositol on the Expression of Mutant Forms of Aquaporin 2

    Article • The Journal of Membrane Biology, July 2010, Springer Science + Business Media

    M.D. DANIEL G BICHET

  86. Race, sex, and the regulation of urine osmolality: observations made during water deprivation

    Article • AJP Regulatory Integrative and Comparative Physiology, June 2010, American Physiological Society

    M.D. DANIEL G BICHET

  87. New autosomal recessive mutations in aquaporin‐2 causing nephrogenic diabetes insipidus through deficient targeting display normal expression in Xenopus oocytes

    Article • The Journal of Physiology, June 2010, Wiley

    M.D. DANIEL G BICHET

  88. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative

    Article • Molecular Genetics and Metabolism, April 2010, Elsevier

    M.D. DANIEL G BICHET

  89. A validated disease severity scoring system for Fabry disease

    Article • Molecular Genetics and Metabolism, March 2010, Elsevier

    M.D. DANIEL G BICHET

  90. Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia

    Article • Journal of the American Society of Nephrology, February 2010, American Society of Nephrology

    M.D. DANIEL G BICHET

  91. Targeted Inactivation of EGF Receptor Inhibits Renal Collecting Duct Development and Function

    Article • Journal of the American Society of Nephrology, February 2010, American Society of Nephrology

    M.D. DANIEL G BICHET

  92. 140. A validated disease severity scoring system for Fabry disease

    Article • Molecular Genetics and Metabolism, February 2010, Elsevier

    M.D. DANIEL G BICHET

  93. 148.A randomized controlled trial of enzyme replacement therapy in Fabry disease: The Canadian Fabry disease initiative at year three

    Article • Molecular Genetics and Metabolism, February 2010, Elsevier

    M.D. DANIEL G BICHET

  94. Assessment of Renal Pathology and Dysfunction in Children with Fabry Disease

    Article • Clinical Journal of the American Society of Nephrology, January 2010, American Society of Nephrology

    M.D. DANIEL G BICHET

  95. Vasopressin Type 2 Receptor V88M Mutation: Molecular Basis of Partial and Complete Nephrogenic Diabetes Insipidus

    Article • Nephron Physiology, January 2010, Karger Publishers

    M.D. DANIEL G BICHET

  96. Secondary Nephrogenic Diabetes Insipidus as a Complication of Inherited Renal Diseases

    Article • Nephron Physiology, January 2010, Karger Publishers

    M.D. DANIEL G BICHET

  97. The Canadian Fabry Disease Initiative: a randomized controlled trial of agalsidase therapy in Fabry nephropathy

    Article • International Journal of Clinical Pharmacology and Therapeutics, December 2009, Dustri-Verlgag Dr. Karl Feistle

    M.D. DANIEL G BICHET

  98. Hereditary nephrogenic diabetes insipidus: a major conundrum during labour and delivery

    Article • Clinical Kidney Journal, August 2009, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  99. Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype

    Article • AJP Renal Physiology, May 2009, American Physiological Society

    Dr Anatoly Tiulpakov, M.D. DANIEL G BICHET

  100. Wilms tumor arising in a child with X-linked nephrogenic diabetes insipidus

    Article • Pediatric Nephrology, March 2009, Springer Science + Business Media

    M.D. DANIEL G BICHET

  101. Nephrogenic Diabetes Insipidus

    Article • January 2009, Elsevier

    M.D. DANIEL G BICHET

  102. Chapter 2 V2R Mutations and Nephrogenic Diabetes Insipidus

    Article • January 2009, Elsevier

    M.D. DANIEL G BICHET

  103. Is Testing with dDAVP Useful in Detecting Carriers of the Nephrogenic Diabetes insipidus Gene?

    Article • December 2008, Karger Publishers

    M.D. DANIEL G BICHET

  104. Rolipram, a Phosphodiesterase Inhibitor, in the Treatment of Two Male Patients with Congenital Nephrogenic Diabetes insipidus

    Article • December 2008, Karger Publishers

    M.D. DANIEL G BICHET

  105. A novel disease-causing mutation in AVPR2: Q96H

    Article • Clinical Kidney Journal, October 2008, Oxford University Press (OUP)

    Dr Mathieu Lemaire, M.D. DANIEL G BICHET

  106. Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists

    Article • Journal of the American Society of Nephrology, August 2008, American Society of Nephrology

    M.D. DANIEL G BICHET

  107. Ethnic Differences in Renal Responses to Furosemide

    Article • Hypertension, July 2008, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  108. Vasopressin Receptor Mutations in Nephrogenic Diabetes Insipidus

    Article • Seminars in Nephrology, May 2008, Elsevier

    M.D. DANIEL G BICHET

  109. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease

    Article • Molecular Genetics and Metabolism, March 2008, Elsevier

    Dr Regen Drouin, M.D. DANIEL G BICHET

  110. Polyuria and Diabetes Insipidus

    Article • January 2008, Elsevier

    M.D. DANIEL G BICHET

  111. Expression and functionality of the Na+/myo-inositol cotransporter SMIT2 in rabbit kidney

    Article • Biochimica et Biophysica Acta (BBA) - Biomembranes, May 2007, Elsevier

    M.D. DANIEL G BICHET

  112. Diabetes insípidas nefrógenas

    Article • EMC - Pediatría, January 2007, Elsevier

    M.D. DANIEL G BICHET

  113. Diabètes insipides néphrogéniques

    Article • EMC - Pédiatrie - Maladies infectieuses, January 2007, Elsevier

    M.D. DANIEL G BICHET

  114. Clinical benefits of early treatment with Fabrazyme in Fabry disease

    Article • Clinical Therapeutics, January 2007, Elsevier

    M.D. DANIEL G BICHET

  115. Deterioration of renal function in young adult patients with fabry disease and proteinuria

    Article • Clinical Therapeutics, January 2007, Elsevier

    M.D. DANIEL G BICHET

  116. Diabètes insipides néphrogéniques

    Article • Néphrologie & Thérapeutique, November 2006, Elsevier

    M.D. DANIEL G BICHET

  117. Elaboration of a novel technique for purification of plasma membranes from Xenopus laevis oocytes

    Article • AJP Cell Physiology, November 2006, American Physiological Society

    M.D. DANIEL G BICHET

  118. Severe combined immunodeficiency associated with nephrogenic diabetes insipidus and a deletion in the Xq28 region

    Article • Clinical Immunology, August 2006, Elsevier

    M.D. DANIEL G BICHET

  119. Water Metabolism

    Article • Seminars in Nephrology, May 2006, Elsevier

    M.D. DANIEL G BICHET

  120. Hereditary Polyuric Disorders: New Concepts and Differential Diagnosis

    Article • Seminars in Nephrology, May 2006, Elsevier

    M.D. DANIEL G BICHET

  121. Nephrogenic Diabetes Insipidus

    Article • Advances in Chronic Kidney Disease, April 2006, Elsevier

    M.D. DANIEL G BICHET

  122. Lithium, Cyclic AMP Signaling, A-Kinase Anchoring Proteins, and Aquaporin-2

    Article • Journal of the American Society of Nephrology, March 2006, American Society of Nephrology

    M.D. DANIEL G BICHET

  123. The dilemma of diagnosing the cause of hypernatraemia: drinking habits vs diabetes insipidus

    Article • Nephrology Dialysis Transplantation, December 2004, Oxford University Press (OUP)

    M.D. DANIEL G BICHET

  124. Pharmacological chaperone action on G-protein-coupled receptors

    Article • Current Opinion in Pharmacology, October 2004, Elsevier

    M.D. DANIEL G BICHET

  125. P011 - Une forme rare de diabète insipide familial : la mutation du gène de la pré-pro AVP

    Article • Annales d Endocrinologie, September 2004, Elsevier

    M.D. DANIEL G BICHET

  126. The quest for the gene responsible for medullarycystic kidney disease type 1

    Article • Kidney International, August 2004, Elsevier

    M.D. DANIEL G BICHET

  127. Functional Rescue of the Constitutively Internalized V2 Vasopressin Receptor Mutant R137H by the Pharmacological Chaperone Action of SR49059

    Article • Molecular Endocrinology, August 2004, Endocrine Society

    M.D. DANIEL G BICHET

  128. Pharmacological chaperones: potential treatment for conformational diseases

    Article • Trends in Endocrinology and Metabolism, July 2004, Elsevier

    M.D. DANIEL G BICHET

  129. Reabsorption of Sodium Chloride — Lessons from the Chloride Channels

    Article • New England Journal of Medicine, March 2004, New England Journal of Medicine (NEJM/MMS)

    M.D. DANIEL G BICHET

  130. Diabètes insipides néphrogéniques

    Article • EMC - Néphrologie, February 2004, Elsevier

    M.D. DANIEL G BICHET

  131. Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus

    Article • The Journal of Cell Biology, December 2003, Rockefeller University Press

    M.D. DANIEL G BICHET

  132. Prix Nobel de Chimie 2003 : canaux hydriques et ioniques

    Article • médecine/sciences, December 2003, EDP Sciences

    M.D. DANIEL G BICHET

  133. Influence of plasma amino acid level on vasopressin secretion

    Article • Diabetes & Metabolism, September 2003, Elsevier

    M.D. DANIEL G BICHET

  134. Un an déjà!

    Article • médecine/sciences, January 2003, EDP Sciences

    M.D. DANIEL G BICHET

  135. Two Novel Aquaporin-2 Mutations Responsible for Congenital Nephrogenic Diabetes Insipidus in Chinese Families

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2002, Endocrine Society

    M.D. DANIEL G BICHET

  136. Life : une étude qui vaprobablement modifiernotre approchedans le traitement del’hypertension artérielle

    Article • médecine/sciences, May 2002, EDP Sciences

    M.D. DANIEL G BICHET

  137. Intrafamilial phenotype variability in nephrogenic diabetes insipidus

    Article • American Journal of Kidney Diseases, April 2002, Elsevier

    M.D. DANIEL G BICHET

  138. Le changement dans la continuité et la continuité dans le changement

    Article • médecine/sciences, January 2002, EDP Sciences

    M.D. DANIEL G BICHET

  139. Three Families with Autosomal Dominant Nephrogenic Diabetes Insipidus Caused by Aquaporin-2 Mutations in the C-Terminus

    Article • The American Journal of Human Genetics, October 2001, Elsevier

    M.D. DANIEL G BICHET

  140. Arginine-vasopressin and oxytocin response to cholecystokinin-tetrapeptide

    Article • Peptides, August 2001, Elsevier

    M.D. DANIEL G BICHET

  141. A patient with partial central diabetes insipidus: Clarifying pathophysiology and designing treatment

    Article • American Journal of Kidney Diseases, June 2001, Elsevier

    M.D. DANIEL G BICHET

  142. Association of Calnexin with Wild Type and Mutant AVPR2 that Cause Nephrogenic Diabetes Insipidus†

    Article • Biochemistry, June 2001, American Chemical Society (ACS)

    M.D. DANIEL G BICHET

  143. Nephrogenic Diabetes Insipidus

    Article • Annual Review of Physiology, March 2001, Annual Reviews

    M.D. DANIEL G BICHET

  144. 2001, Odyssée de la Science.

    Article • médecine/sciences, January 2001, INIST-CNRS

    M.D. DANIEL G BICHET

  145. Structure de l'aquaporine 1 ou comment bloquer un bâton de relais (le proton) qui se déplace plus vite que le coureur (l'eau) ?

    Article • médecine/sciences, January 2001, INIST-CNRS

    M.D. DANIEL G BICHET

  146. Pharmacological chaperones: a new twist on receptor folding

    Article • Trends in Pharmacological Sciences, December 2000, Elsevier

    M.D. DANIEL G BICHET

  147. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

    Article • Journal of Clinical Investigation, April 2000, American Society for Clinical Investigation

    M.D. DANIEL G BICHET

  148. Des chaperons pharmacologiques pour corriger le diabète insipide néphrogénique ?

    Article • médecine/sciences, January 2000, INIST-CNRS

    M.D. DANIEL G BICHET

  149. The Relationship Among Carbon Dioxide Pneumoperitoneum, Vasopressin Release, and Hemodynamic Changes

    Article • Anesthesia & Analgesia, August 1999, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  150. The Relationship Among Carbon Dioxide Pneumoperitoneum, Vasopressin Release, and Hemodynamic Changes

    Article • Anesthesia & Analgesia, August 1999, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  151. Metabolic and Antihypertensive Effects of Nebivolol and Atenolol in Normometabolic Patients with Mild-to-Moderate Hypertension

    Article • American Journal of Therapeutics, May 1999, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  152. Diversity of nephrogenic diabetes insipidus mutations and importance of early recognition and treatment

    Article • Clinical and Experimental Nephrology, December 1998, Springer Science + Business Media

    M.D. DANIEL G BICHET

  153. Nephrogenic diabetes insipidus11In collaboration with The American Physiological Society, Thomas E. Andreoli, MD, Editor

    Article • The American Journal of Medicine, November 1998, Elsevier

    M.D. DANIEL G BICHET

  154. The role of the β-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms

    Article • Biological Psychiatry, September 1998, Elsevier

    M.D. DANIEL G BICHET

  155. Hyponatremia in cirrhosis: From pathogenesis to treatment

    Article • Hepatology, September 1998, Wiley

    M.D. DANIEL G BICHET

  156. Nephrogenic Diabetes Insipidus and Vasopressin Receptor Mutations

    Article • January 1998, Springer Science + Business Media

    M.D. DANIEL G BICHET

  157. Chapter 7 Two genes-one disease: The molecular basis of congenital nephrogenic diabetes insipidus

    Article • January 1998, Elsevier

    M.D. DANIEL G BICHET

  158. Diabètes insipides héréditaires : un nouveau gène responsable du syndrome de Wolfram.

    Article • médecine/sciences, January 1998, INIST-CNRS

    M.D. DANIEL G BICHET

  159. Functional Study of Two V2 Vasopressin Mutant Receptors Related to NDI

    Article • January 1998, Springer Science + Business Media

    M.D. DANIEL G BICHET

  160. Étude fonctionnelle de mutations du gène due récepteur V2 responsables d'un diabète insipide néphrogénique congénital

    Article • Archives de Pédiatrie, December 1997, Elsevier

    M.D. DANIEL G BICHET

  161. Biochemical Basis of Partial Nephrogenic Diabetes Insipidus Phenotypes

    Article • Molecular Endocrinology, November 1997, Endocrine Society

    M.D. DANIEL G BICHET

  162. Influence of type A behaviour pattern on response to CCK-4

    Article • Biological Psychiatry, July 1997, Elsevier

    M.D. DANIEL G BICHET

  163. Chloride channels and hypercalciuria: an unturned stone.

    Article • Journal of Clinical Investigation, March 1997, American Society for Clinical Investigation

    M.D. DANIEL G BICHET

  164. Posterior Pituitary Hormones

    Article • January 1997, Springer Science + Business Media

    M.D. DANIEL G BICHET

  165. Les diabètes insipides néphrogéniques héréditaires

    Article • médecine/sciences, January 1997, INIST-CNRS

    M.D. DANIEL G BICHET

  166. Étude fonctionnelle de mutations du gène du récepteur V2 responsables d'un diabète insipide néphrogénique congénital

    Article • Archives de Pédiatrie, January 1997, Elsevier

    M.D. DANIEL G BICHET

  167. Étude fonctionnelle de deux mutations du gène du RV2, responsables d'un diabète insipide néphrogénique lié à l'X

    Article • Archives de Pédiatrie, December 1996, Elsevier

    M.D. DANIEL G BICHET

  168. Two novel mutations in the aquaporin-2 and the vasopressin V2 receptor genes in patients with congenital nephrogenic diabetes insipidus

    Article • Human Genetics, September 1996, Springer Science + Business Media

    M.D. DANIEL G BICHET

  169. A Peptide Derived from a  2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation

    Article • Journal of Biological Chemistry, July 1996, American Society for Biochemistry & Molecular Biology (ASBMB)

    M.D. DANIEL G BICHET

  170. Vasopressin receptors in health and disease

    Article • Kidney International, June 1996, Elsevier

    M.D. DANIEL G BICHET

  171. Molecular analysis of X-linked nephrogenic diabetes insipidus

    Article • European Journal of Endocrinology, June 1996, Bioscientifica

    M.D. DANIEL G BICHET

  172. Effect of a major depressive episode history on the CCK-4 response in women

    Article • European Neuropsychopharmacology, June 1996, Elsevier

    M.D. DANIEL G BICHET

  173. The role of the seta adrenergic system in CCK-4 induced panic symptoms

    Article • European Neuropsychopharmacology, June 1996, Elsevier

    M.D. DANIEL G BICHET

  174. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease

    Article • Pediatric Nephrology, April 1996, Springer Science + Business Media

    M.D. DANIEL G BICHET

  175. P-1-4 The effects of CCK-4 on plasma arginine-vasopressin and oxytocin levels in women with and without premenstrual dysphoric disorder

    Article • European Neuropsychopharmacology, September 1995, Elsevier

    M.D. DANIEL G BICHET

  176. Diabetes insipidus

    Article • Baillière s Clinical Endocrinology and Metabolism, July 1995, Elsevier

    M.D. DANIEL G BICHET

  177. Urinary Excretion of Aquaporin-2 in Patients with Diabetes Insipidus

    Article • New England Journal of Medicine, June 1995, New England Journal of Medicine (NEJM/MMS)

    M.D. DANIEL G BICHET

  178. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease

    Article • Genomics, February 1995, Elsevier

    M.D. DANIEL G BICHET

  179. MOLECULAR BIOLOGY OF DIABETES INSIPIDUS

    Article • Annual Review of Medicine, February 1995, Annual Reviews

    M.D. DANIEL G BICHET

  180. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril

    Article • Journal of the American College of Cardiology, September 1994, Elsevier

    M.D. DANIEL G BICHET

  181. Autosomal dominant polycystic kidney disease in the fetus

    Article • American Journal of Medical Genetics, July 1994, Wiley

    M.D. DANIEL G BICHET

  182. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction

    Article • Circulation, May 1994, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  183. Atrial natriuretic peptide release from the ventricles in response to exercise in dogs with atrioventricular block

    Article • Canadian Journal of Physiology and Pharmacology, February 1994, Canadian Science Publishing

    M.D. DANIEL G BICHET

  184. Molecular and cellular biology of vasopressin and oxytocin receptor and action in the kidney

    Article • Current Opinion in Nephrology & Hypertension, January 1994, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  185. X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis.

    Article • Journal of Clinical Investigation, September 1993, American Society for Clinical Investigation

    M.D. DANIEL G BICHET

  186. Activation of neurohumoral systems in postinfarction left ventricular dysfunction

    Article • Journal of the American College of Cardiology, August 1993, Elsevier

    M.D. DANIEL G BICHET

  187. The vasopressin type 2 receptor gene. Chromosomal localization and its role in nephrogenic diabetes insipidus

    Article • Regulatory Peptides, April 1993, Elsevier

    M.D. DANIEL G BICHET

  188. The Hemodynamic and Coagulant Effects of DDAVP Are Specific Extrarenal V2- Receptor Responses

    Article • January 1993, Springer Science + Business Media

    M.D. DANIEL G BICHET

  189. The Vasopressin Antagonist Sk&F 105494 Inhibits Desmopressin-Stimulated Clotting Factor Release in Vivo

    Article • January 1993, Springer Science + Business Media

    M.D. DANIEL G BICHET

  190. Influence of the level of hydration on the renal response to a protein meal

    Article • Kidney International, November 1992, Elsevier

    M.D. DANIEL G BICHET

  191. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus

    Article • Nature, September 1992, Nature

    M.D. DANIEL G BICHET

  192. Activation of neurohumoral systems following acute myocardial infarction

    Article • The American Journal of Cardiology, November 1991, Elsevier

    M.D. DANIEL G BICHET

  193. Platelet vasopressin receptors in patients with congenital nephrogenic diabetes insipidus

    Article • Kidney International, April 1991, Elsevier

    M.D. DANIEL G BICHET

  194. Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers

    Article • Biopharmaceutics & Drug Disposition, March 1991, Wiley

    M.D. DANIEL G BICHET

  195. Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure

    Article • Biopharmaceutics & Drug Disposition, March 1991, Wiley

    M.D. DANIEL G BICHET

  196. Selective activation of neurohormonal systems in post-infarction left ventricular dysfunction

    Article • Journal of the American College of Cardiology, February 1991, Elsevier

    M.D. DANIEL G BICHET

  197. Sustained beneficial effect of a seventy-two hour intravenous infusion of nitroglycerin in patients with severe chronic congestive heart failure

    Article • American Heart Journal, September 1990, Elsevier

    M.D. DANIEL G BICHET

  198. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus

    Article • Kidney International, November 1989, Elsevier

    M.D. DANIEL G BICHET

  199. 12 Water disturbances in cardiac failure

    Article • Baillière s Clinical Endocrinology and Metabolism, August 1989, Elsevier

    M.D. DANIEL G BICHET

  200. Arginine-vasopressin in congenital nephrogenic diabetes insipidus

    Article • Biomedicine & Pharmacotherapy, January 1989, Elsevier

    M.D. DANIEL G BICHET

  201. Effect of induced ventricular tachycardia on atrial natriuretic peptide in humans

    Article • Journal of the American College of Cardiology, December 1988, Elsevier

    M.D. DANIEL G BICHET

  202. Neurohumoral and hemodynamic changes in congestive heart failure: Lack of correlation and evidence of compensatory mechanisms

    Article • American Heart Journal, September 1988, Elsevier

    M.D. DANIEL G BICHET

  203. Atrial natriuretic peptide in congestive heart failure: Postural changes and reset with chronic captopril therapy

    Article • American Heart Journal, May 1988, Elsevier

    M.D. DANIEL G BICHET

  204. Hemodynamic and Coagulation Responses to 1-Desamino[8-D-Arginine] Vasopressin in Patients with Congenital Nephrogenic Diabetes Insipidus

    Article • New England Journal of Medicine, April 1988, New England Journal of Medicine (NEJM/MMS)

    M.D. DANIEL G BICHET

  205. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure

    Article • Journal of the American College of Cardiology, March 1987, Elsevier

    M.D. DANIEL G BICHET

  206. Human platelet fraction arginine-vasopressin. Potential physiological role.

    Article • Journal of Clinical Investigation, March 1987, American Society for Clinical Investigation

    M.D. DANIEL G BICHET

  207. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure

    Article • Kidney International, June 1986, Elsevier

    M.D. DANIEL G BICHET

  208. Sodium excretion in advanced cirrhosis: Effect of expansion of central blood volume and suppression of plasma aldosterone

    Article • Hepatology, March 1986, Wiley

    M.D. DANIEL G BICHET

  209. Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity

    Article • Circulation, March 1986, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  210. Hypersécrétion de l'hormone antidiurétique chez l'homme

    Article • médecine/sciences, January 1986, INIST-CNRS

    M.D. DANIEL G BICHET

  211. Syndrome of Inappropriate Antidiuresis in the Absence of Arginine Vasopressin*

    Article • The Journal of Clinical Endocrinology & Metabolism, January 1986, Endocrine Society

    M.D. DANIEL G BICHET

  212. Vasopressin in Congestive Heart Failure

    Article • Journal of Cardiovascular Pharmacology, January 1986, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  213. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients

    Article • Kidney International, August 1985, Elsevier

    M.D. DANIEL G BICHET

  214. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion

    Article • Circulation Research, March 1985, Wolters Kluwer Health

    M.D. DANIEL G BICHET

  215. Role of Arginine-Vasopressin (AVP) in Stress-Induced Inhibition of Testicular Steroidogenesis in Normal and in AVP-Deficient Rats*

    Article • Endocrinology, October 1984, Endocrine Society

    M.D. DANIEL G BICHET

  216. Treatment of Hypoosmolar and Hyperosmolar States

    Article • January 1984, Springer Science + Business Media

    M.D. DANIEL G BICHET

  217. Effect of Head-Out Water Immersion on Hepatorenal Syndrome

    Article • American Journal of Kidney Diseases, January 1984, Elsevier

    M.D. DANIEL G BICHET

  218. Sodium and Water Excretion in Patients with Congestive Heart Failure and Cirrhosis

    Article • January 1984, Springer Science + Business Media

    M.D. DANIEL G BICHET

  219. Mechanisms of improvement of water and sodium excretion by immersion in decompensated cirrhotic patients

    Article • Kidney International, December 1983, Elsevier

    M.D. DANIEL G BICHET

  220. Potential Role of Increased Sympathetic Activity in Impaired Sodium and Water Excretion in Cirrhosis

    Article • New England Journal of Medicine, December 1982, New England Journal of Medicine (NEJM/MMS)

    M.D. DANIEL G BICHET

  221. Role of Vasopressin in Abnormal Water Excretion in Cirrhotic Patients

    Article • Annals of Internal Medicine, April 1982, American College of Physicians

    M.D. DANIEL G BICHET

  222. EVIDENCE AGAINST CONCEPT OF HYPONATRAEMIA AND "SICK CELLS"

    Article • The Lancet, March 1982, Elsevier

    M.D. DANIEL G BICHET

  223. Renal intracortical blood flow and renin secretion after denervation by 6-hydroxydopamine

    Article • Canadian Journal of Physiology and Pharmacology, February 1982, Canadian Science Publishing

    M.D. DANIEL G BICHET

  224. Radioimmunoassay of Plasma Arginine Vasopressin in Hyponatremic Patients with Congestive Heart Failure

    Article • New England Journal of Medicine, July 1981, New England Journal of Medicine (NEJM/MMS)

    M.D. DANIEL G BICHET

  225. Prevention and Pathogenesis of Acute Renal Failure

    Article • Clinical and Experimental Dialysis and Apheresis, January 1981, Taylor & Francis

    M.D. DANIEL G BICHET

  226. Increased circulating plasma catecholamines and plasma renin activity in dogs after chemical sympathectomy with 6-hydroxydopamine

    Article • Canadian Journal of Physiology and Pharmacology, June 1977, Canadian Science Publishing

    M.D. DANIEL G BICHET

  227. Posterior Pituitary Hormones

    Article • Springer Science + Business Media

    M.D. DANIEL G BICHET

  228. Nephrogenic Diabetes Insipidus st[Water and Urea Transport

    Article • Springer Science + Business Media

    M.D. DANIEL G BICHET

  229. Insuffisance posthypophysaire au cours de la grossesse

    Article • Springer Science + Business Media

    M.D. DANIEL G BICHET